Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma

Stupp, Roger; Taillibert, Sophie; A. Kanner, Andrew; Kesari, Santosh; M. Steinberg, David; A. Toms, Steven; P. Taylor, Lynne; S. Lieberman, Frank; Silvani, Antonio; Fink, Karen; H. Barnett, Gene; Zhu, Jay‐Jiguang; W. Henson, John; H. Engelhard, Herbert; C. Chen, Thomas; Tran, David; Šroubek, Jan; Tran, Nam; F. Hottinger, Andreas; Landolfi, Joseph; Desai, Rajiv; Caroli, Manuela; Kew, Yvonne; Honnorat, Jérôme; Idbaïh, Ahmed; D. Kirson, Eilon; Weinberg, Uri; Palti, Yoram; E. Hegi, Monika; Ram, Zvi

doi:10.1001/jama.2015.16669

Public

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma

Published in JAMA • Dec 15, 2015

Authors:

Roger Stupp

Sophie Taillibert

Andrew A. Kanner

Abstract

IMPORTANCE: Glioblastoma is the most devastating primary malignancy of the central nervous system in adults. Most patients die within 1 to 2 years of diagnosis. Tumor-treating fields (TTFields) are a locoregionally delivered antimitotic treatment that interferes with cell division and organelle asse...

Subject

Temozolomide

Medicine

Interim analysis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!